Skip to main content
TipRanks
Go Ultimate75% OFF

Crinetics presents long-term data from program evaluating Palsonify

Crinetics (CRNX) Pharmaceuticals announced new long-term data from its clinical development program evaluating novel Palsonify in acromegaly during an oral presentation at the Endocrine Society’s Annual Meeting, ENDO 2026. Notably, pooled data from the open-label extension, OLE, trials of Pathfndr-1 and Pathfndr-2 show that after two years of treatment, Palsonify was effective and well-tolerated in patients who were switched from standard-of-care monthly injectable somatostatin receptor ligands and those who were medically untreated, respectively, when oral, once-daily Palsonify was initiated.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

Add as preferred source